Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115562
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115562
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115562
Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer
Yun-Yun Lu, Yi Lu, Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo 315048, Zhejiang Province, China
Pan Chen, Zhejiang Key Laboratory of Pathophysiology, Health Science Center, Ningbo 315211, Zhejiang Province, China
Author contributions: Lu YY contributed to study concept and design, acquisition of data, analysis, and interpretation of data and drafting of the manuscript; Chen P and Lu P contributed to study concept and design, analysis and interpretation of data, and study supervision.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Ningbo Medical Center Lihuili Hospital.
Informed consent statement: The retrospective design of the study led to a waiver of informed consent.
Conflict-of-interest statement: All remaining authors have declared no conflicts of interest.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun-Yun Lu, Professor, Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, No. 1111 Jiangnan Road, Ningbo 315048, Zhejiang Province, China. lhlluyunyun@nbu.edu.cn
Received: October 24, 2025
Revised: November 13, 2025
Accepted: December 11, 2025
Published online: February 15, 2026
Processing time: 106 Days and 4.2 Hours
Revised: November 13, 2025
Accepted: December 11, 2025
Published online: February 15, 2026
Processing time: 106 Days and 4.2 Hours
Core Tip
Core Tip: This study identified prognostic factors for older patients with advanced pancreatic cancer treated with programmed death-1 (PD-1) inhibitors. The findings indicated that PD-1 inhibitor therapy was safe in this older population. Key predictors of treatment prognosis included the Eastern Cooperative Oncology Group performance status, prognostic nutritional index, and triglyceride levels.